ChiCTR-INC-16009306
正在进行
/
化药
美乐托宁
2016-10-03
/
卵巢储备功能下降
褪黑素联合DHEA治疗卵巢储备功能下降的临床试验
褪黑素联合DHEA治疗卵巢储备功能下降的临床试验
410008
The aim of the study is whether oral melatonin plus DHEA administration can improve the outcome of IVF in Diminished Ovarian Reserve (DOR) patients as follows: To determine embryological outcome; To determine biochemical outcome (to find out optimum hormono-microfollicular enviroment for high quality oocyte through comparing Melatonin, Estrogen, Progestrogen and LH in follicular fluidin leading follicles of different group patients including PCOS, Normal Ovarian Reserve, DOR patients with or without Melatonin plus DHEA treated).
横断面
治疗新技术
Randomization will be computerized.
/
中南大学湘雅医院生殖医学中心
/
50
/
2016-09-25
2017-02-27
/
For DOR patient: The criteria for DOR included AMH, FSH and Estradiol (E2) levels as well as antral follicle counts (AFC) or retrieved oocyte number. The patients were considered to have DOR if they have had serum AMH levels ≤ 1 ng/ml or an AFC≤5 on Day 3 of a spontaneous cycle or retrieved oocyte number ≤3. For NOR patient (Normal Ovarian Reserve): The criteria for Normal Ovarian Reserve (NOR) patients included AMH>3 ng/ml, FSH≤10 IU/ml, an AFC≥8 and or retrieved oocyte number ≥6. For PCOS patient: The criteria for PCOS patients included AMH>10 ng/ml, FSH/LH ratio >2, AFC for each ovaries ≥ 12(Total ≥ 25) and or retrieved oocyte number ≥ 15 or clinical and/or biochemical signs of hyperandrogenism.；
请登录查看The patients with known conditions affecting ovarian reserve, including ovarian surgery, polycystic ovarian syndrome, endometriosis, post chemo and radiation therapy recovery or BMI ≥ 25 will be excluded.；
请登录查看中南大学湘雅医院生殖医学中心
410008
中南大学湘雅医院生殖医学中心的其他临床试验
中南大学湘雅医院生殖医学中心的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04